

The PASSAGE Program: a structured multicomponent interdisciplinary group intervention for the self-management of chronic low back pain

Submission date 26/08/2014	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 08/10/2014	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 08/10/2014	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Chronic low back pain (CLBP) is a widespread health problem associated with significant costs. The aim of this study is to assess the performance of an intervention called the PASSAGE programme, which has been developed as a series of group therapy sessions to both alleviate symptoms and help patients to self-manage their symptoms.

Who can participate?

Patients who are aged 18 or over with a medical diagnosis of non-specific CLBP and motivated to fully participate in the PASSAGE programme.

What does the study involve?

Participants are randomly allocated to one of two groups: either the intervention group or the waitlist group. Participants in the intervention group attend eight group sessions (with eight people in each group). Each session covers practical and emotional techniques for coping with CLBP (psycho-education), cognitive behavioral therapy-related techniques and exercise activities. A follow-up group session then takes place six months after the completion of the programme. Participants in the waitlist group continue with their usual treatment until the first group completes the PASSAGE programme, after which they also take part. A series of questionnaires completed by both groups are used to assess how well the intervention performs.

What are the possible benefits and risks of participating?

Possible benefits include better self-management of CLBP and alleviation of symptoms. There is little risk in taking part in the study, the only inconvenience being giving up time and resources to participate in the research (e.g. traveling, completing questionnaires).

Where is the study run from?

The University of Sherbrooke (Canada).

When is the study starting and how long is it expected to run for?
January 2010 to October 2011.

Who is funding the study?
Community Alliances for Health Research and Knowledge Exchange in Pain of the Canadian Institutes of Health Research (CIHR) in partnership with AstraZeneca Canada Inc (Grant # 86787), and by Pfizer Canada Inc.

Who is the main contact?
Dr Manon Choinière
manon.choiniere@umontreal.ca

Contact information

Type(s)
Scientific

Contact name
Dr Manon Choinière

Contact details
Centre de recherche du Centre hospitalier de l'Université de Montréal
Tour Saint-Antoine
850, rue Saint-Denis
Bureau S03-428
Montreal
Canada
H2X 0A9
+1 (0) 514 890 8000, ext. 14082
manon.choiniere@umontreal.ca

Additional identifiers

Study information

Scientific Title
Multicomponent interdisciplinary group intervention for the self-management of non-specific chronic low back pain: A multicenter randomized controlled trial

Acronym
PASSAGE

Study objectives
The aim of the present study was to evaluate the efficacy of the PASSAGE Program-a multicomponent interdisciplinary group intervention for the self-management of non-specific chronic low back pain for improving the clinical condition of patients suffering from this type of disorder.

Ethics approval required
Old ethics approval format

Ethics approval(s)

Ethics Committees of the University of Sherbrooke (Université de Sherbrooke), 15/05/2009, ref. 09-034

University of Québec in Abitibi-Témiscamingue (Université de Québec en Abitibi-Témiscamingue) 26/05/2009

Study design

Multicenter open-label randomized wait-list controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Non-specific chronic low back pain

Interventions

1. Intervention group: The PASSAGE program is a structured multicomponent interdisciplinary group intervention aimed at reducing CLBP symptoms and maintaining optimal function through the use of self-management strategies and patient education. The intervention consists of 8 group sessions with 8 participants lasting 2.5h each. Each session involved 3 major components:
 - 1.a. Psycho-educational tools
 - 1.b. Cognitive behavioral therapy-related techniques
 - 1.c. Patient-tailored exercise activities. A follow-up group session is schedule 6 months after the end of the intervention
2. Waitlist group: Participants randomized to the waitlist group were instructed to continue their treatment as usual until they could take part in the PASSAGE Program - i.e., 3 months after the intervention group had completed the program.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Pain intensity, measured with a standardized numerical rating scale (NRS)

Key secondary outcome(s)

1. Progress during rehabilitation treatment (Quebec Back Pain Disability Scale)
2. Pain interference (Brief Pain Inventory)
3. Impact of pain on sleep quality (Chronic Pain Sleep Inventory)
4. Pain coping strategies and (Coping Strategy Questionnaire)
5. Tendency to catastrophize (Pain Catastrophizing Scale)
6. Depressive symptoms (The Beck Depression Inventory)
7. Health-related quality of life (SF-12v2)
8. Patient global impression of change (PGIC)
9. Perceived pain relief (0 to 100% Pain Relief Scale)

Quantitative data were collected in both study groups at baseline (T0), after the intervention group completed the eight sessions of the PASSAGE Program (T1), and 3 months later (T2).

Completion date

01/10/2011

Eligibility

Key inclusion criteria

1. Aged 18 years or older
2. Had a medical diagnosis of non-specific CLBP based on recognized criteria.
3. Reported pain of at least moderate intensity (at least 4/10) in the seven days prior to enrolment
4. Were motivated to attend all group sessions and to integrate the proposed self-management strategies
5. Agreed to not introduce new medications or treatments/therapies over the course of the PASSAGE program

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Subjects who reported major pain syndromes other than CLBP such as arthritis or life threatening diseases such as cancer
2. Physical/psychiatric disorders that could compromise their participation in the study

Date of first enrolment

01/01/2010

Date of final enrolment

01/10/2011

Locations

Countries of recruitment

Canada

Study participating centre

Centre de recherche du Centre hospitalier de l'Université de Montréal
Montreal
Canada
H2X 0A9

Sponsor information**Organisation**

Centre de recherche du Centre hospitalier universitaire de Sherbrooke (Canada)

ROR

<https://ror.org/020r51985>

Funder(s)**Funder type**

Other

Funder Name

Community Alliances for Health Research and Knowledge Exchange in Pain of the Canadian Institutes of Health Research (CIHR) (Canada)

Funder Name

AstraZeneca Canada Inc. (Grant # 86787) (Canada)

Funder Name

Pfizer Canada Inc. (Canada)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration